Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 11(3): e0149782, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26950211

RESUMO

INTRODUCTION: Cholestasis is characterized by accumulation of bile acids and inflammation, causing hepatocellular damage. Still, liver damage markers are highest in acute cholestasis and drop when this condition becomes chronic, indicating that hepatocytes adapt towards the hostile environment. This may be explained by a hormetic response in hepatocytes that limits cell death during cholestasis. AIM: To investigate the mechanisms that underlie the hormetic response that protect hepatocytes against experimental cholestatic conditions. METHODS: HepG2.rNtcp cells were preconditioned (24 h) with sub-apoptotic concentrations (0.1-50 µM) of various bile acids, the superoxide donor menadione, TNF-α or the Farsenoid X Receptor agonist GW4064, followed by a challenge with the apoptosis-inducing bile acid glycochenodeoxycholic acid (GCDCA; 200 µM for 4 h), menadione (50 µM, 6 h) or cytokine mixture (CM; 6 h). Levels of apoptotic and necrotic cell death, mRNA expression of the bile salt export pump (ABCB11) and bile acid sensors, as well as intracellular GCDCA levels were analyzed. RESULTS: Preconditioning with the pro-apoptotic bile acids GCDCA, taurocholic acid, or the protective bile acids (tauro)ursodeoxycholic acid reduced GCDCA-induced caspase-3/7 activity in HepG2.rNtcp cells. Bile acid preconditioning did not induce significant levels of necrosis in GCDCA-challenged HepG2.rNtcp cells. In contrast, preconditioning with cholic acid, menadione or TNF-α potentiated GCDCA-induced apoptosis. GCDCA preconditioning specifically reduced GCDCA-induced cell death and not CM- or menadione-induced apoptosis. The hormetic effect of GCDCA preconditioning was concentration- and time-dependent. GCDCA-, CDCA- and GW4064- preconditioning enhanced ABCB11 mRNA levels, but in contrast to the bile acids, GW4064 did not significantly reduce GCDCA-induced caspase-3/7 activity. The GCDCA challenge strongly increased intracellular levels of this bile acid, which was not lowered by GCDCA-preconditioning. CONCLUSIONS: Sub-toxic concentrations of bile acids in the range that occur under normal physiological conditions protect HepG2.rNtcp cells against GCDCA-induced apoptosis, which is independent of FXR-controlled changes in bile acid transport.


Assuntos
Ácidos e Sais Biliares/farmacologia , Ácidos e Sais Biliares/toxicidade , Colestase/induzido quimicamente , Colestase/prevenção & controle , Hormese , Hepatopatias/complicações , Membro 11 da Subfamília B de Transportadores de Cassetes de Ligação de ATP , Transportadores de Cassetes de Ligação de ATP/genética , Apoptose/efeitos dos fármacos , Colestase/complicações , Colestase/patologia , Citocinas/metabolismo , Citoproteção/efeitos dos fármacos , Células Hep G2 , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Hepatócitos/patologia , Humanos , Isoxazóis/farmacologia , Espécies Reativas de Oxigênio/metabolismo , Receptores Citoplasmáticos e Nucleares/agonistas , Receptores Citoplasmáticos e Nucleares/metabolismo , Fatores de Tempo , Ativação Transcricional/efeitos dos fármacos , Fator de Necrose Tumoral alfa/farmacologia , Vitamina K 3/farmacologia
2.
Neurobiol Dis ; 46(3): 607-24, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22426390

RESUMO

The terms "neuroacanthocytosis" (NA) and "neurodegeneration with brain iron accumulation" (NBIA) both refer to groups of genetically heterogeneous disorders, classified together due to similarities of their phenotypic or pathological findings. Even collectively, the disorders that comprise these sets are exceedingly rare and challenging to study. The NBIA disorders are defined by their appearance on brain magnetic resonance imaging, with iron deposition in the basal ganglia. Clinical features vary, but most include a movement disorder. New causative genes are being rapidly identified; however, the mechanisms by which mutations cause iron accumulation and neurodegeneration are not well understood. NA syndromes are also characterized by a progressive movement disorder, accompanied by cognitive and psychiatric features, resulting from mutations in a number of genes whose roles are also basically unknown. An overlapping feature of the two groups, NBIA and NA, is the occurrence of acanthocytes, spiky red cells with a poorly-understood membrane dysfunction. In this review we summarise recent developments in this field, specifically insights into cellular mechanisms and from animal models. Cell membrane research may shed light upon the significance of the erythrocyte abnormality, and upon possible connections between the two sets of disorders. Shared pathophysiologic mechanisms may lead to progress in the understanding of other types of neurodegeneration.


Assuntos
Encéfalo/patologia , Eritrócitos/fisiologia , Ferro/fisiologia , Doenças Neurodegenerativas/patologia , Animais , Autofagia/fisiologia , Química Encefálica/fisiologia , Humanos , Ferro/sangue , Ferro/metabolismo , Neuroacantocitose/patologia , Doenças Neurodegenerativas/sangue
3.
J Cell Physiol ; 227(4): 1285-90, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21618525

RESUMO

Mammalian hibernation consists of periods of depressed metabolism and reduced body temperature called "torpor" that are interspersed by normothermic arousal periods. Numerous cellular processes are halted during torpor, including transcription, translation, and ion homeostasis. Hibernators are able to survive long periods of low blood flow and body temperature followed by rewarming and reperfusion without overt signs of organ injury, which makes these animals excellent models for application of natural protective mechanisms to human medicine. This review examines efforts to induce torpor-like states in non-hibernating species using pharmacological compounds. Elucidating the underlying mechanisms of natural and pharmacologically induced torpor will speed the development of new clinical approaches to treat a variety of trauma and stress states in humans.


Assuntos
Hibernação/fisiologia , Monofosfato de Adenosina/farmacologia , Animais , Sobrevivência Celular , Leucina Encefalina-2-Alanina/farmacologia , Hibernação/efeitos dos fármacos , Hibernação/genética , Humanos , Sulfeto de Hidrogênio/farmacologia , Modelos Animais , Peptídeos , Proteínas/farmacologia , Proteínas/fisiologia , Estresse Fisiológico , Tironinas/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...